Active — Not RecruitingEarly Phase 1

PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer

United States25 participantsStarted 2018-09-07

Plain-language summary

This trial studies how well positron emission tomography/magnetic resonance imaging (PET/MRI) scan works in checking patients with stage IA1-IB3 cervical cancer that can be removed by surgery (resectable). PET/MRI scan may help doctors learn more about the spread of the disease.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients with suspected clinical stage IA1-IB3 cervical cancer except patients with tumors \> 4 cm * No contraindications to MRI * Patients undergoing surgical procedure at MD Anderson * Suspected cervical cancer Exclusion Criteria: * Patients who have contraindication to MRI * Glomerular filtration rate (GFR) \< 30 * Pregnant patients * Patients with history of previous radiation * Patients with previous surgery for cervical cancer, unless residual tumor noted on physical exam * Patients with endometrial cancer extending to the cervix * Allergic reaction to gadolinium based contrast * Body weight of greater than 450 (181.4 kg) * Patients requiring general sedation * Extremely claustrophobic patients

What they're measuring

Accuracy of diagnosing depth of invasion on positron emission tomography/magnetic resonance imaging (PET/MRI)

Timeframe: 3 years

Trial details

NCT IDNCT04219904

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-09-30

View on ClinicalTrials.gov More Stage IA Cervical Cancer trials